Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Macro

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2004
Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'AdulteN Mounier, C Gisselbrecht, J Brière, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2004
All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA)N Mounier, C Gisselbrecht, J Brière, et al.
European Journal of Nuclear Medicine|February 7, 2001
Clinical relevance of gallium-67 scintigraphy in lymphoma before and after therapyC Delcambre, O Reman, M Henry-Amar, et al.
The Journal of Rheumatology|August 26, 1998
A randomized, double blind, placebo controlled multicenter trial of murine anti-CD4 monoclonal antibody therapy in rheumatoid arthritisD Wendling, E Racadot, J Wijdenes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 26, 2009
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma NetworkE Terpos, O Sezer, P I Croucher, et al.
La Revue De Medecine Interne|August 11, 2015
[Pomalidomide for multiple myeloma]G Fouquet, M Macro, O Decaux, et al.
Annals of Hematology|June 10, 2023
Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX studyM Macro, C Hulin, L Vincent, et al.
British Journal of Haematology|September 14, 2024
Teclistamab for relapsed refractory multiple myeloma patients on dialysisP Lebreton, F Lachenal, S Bouillie, et al.
Leukemia|July 30, 2011
Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experienceH Avet-Loiseau, M Roussel, L Campion, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 27, 2024
Real-Life Management of Patients Aged 80 Years Old and Over With Multiple Myeloma: Results of the EMMY CohortT Chalopin, M Macro, O Decaux, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2004
Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'AdulteN Mounier, C Gisselbrecht, J Brière, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2004
All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA)N Mounier, C Gisselbrecht, J Brière, et al.
European Journal of Nuclear Medicine|February 7, 2001
Clinical relevance of gallium-67 scintigraphy in lymphoma before and after therapyC Delcambre, O Reman, M Henry-Amar, et al.
The Journal of Rheumatology|August 26, 1998
A randomized, double blind, placebo controlled multicenter trial of murine anti-CD4 monoclonal antibody therapy in rheumatoid arthritisD Wendling, E Racadot, J Wijdenes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 26, 2009
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma NetworkE Terpos, O Sezer, P I Croucher, et al.
La Revue De Medecine Interne|August 11, 2015
[Pomalidomide for multiple myeloma]G Fouquet, M Macro, O Decaux, et al.
Annals of Hematology|June 10, 2023
Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX studyM Macro, C Hulin, L Vincent, et al.
British Journal of Haematology|September 14, 2024
Teclistamab for relapsed refractory multiple myeloma patients on dialysisP Lebreton, F Lachenal, S Bouillie, et al.
Leukemia|July 30, 2011
Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experienceH Avet-Loiseau, M Roussel, L Campion, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 27, 2024
Real-Life Management of Patients Aged 80 Years Old and Over With Multiple Myeloma: Results of the EMMY CohortT Chalopin, M Macro, O Decaux, et al.
Pageof 6